

Twilight Litaka Pharma Limited

Regd. Office : Himalaya Estate, 16-A Shivajinagar, Pune 411 005

Page 1 of 2

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2011

(Rs.in Lac)

S No.	Particulars	Quarter Ended		Half Year Ended		Financial
		(Unaudited)		(Unaudited)		Year Ended
		30.09.2011	30.09.2010	30.09.2011	30.09.2010	( Audited )
						31.03.2011
1	a. Net Sales / Income From Operations	18065.15	17102.62	36421.14	32287.68	65678.11
	b. Other Operating Income	-	-	-	-	-
2	Expenditure					
	a Increase/decrease in stock in trade & WIP	6.88	-358.29	-163.33	-655.55	-778.19
	b Consumption of Raw material	12168.33	12229.99	25035.44	23239.72	46721.12
	c Purchase of traded goods.	1577.12	1246.25	2934.41	2349.21	4643.94
	d Employee cost	513.99	430.36	991.56	852.16	1767.93
	e Depreciation	144.80	88.78	249.09	177.29	364.87
	f Other expenditure	1167.22	972.22	2196.68	1799.43	3806.45
	g Expenditure (a to f)	15578.34	14609.31	31243.85	27762.26	56526.12
	<b>Profit from Operations before Other Income, Interest and</b>					
3	<b>Exceptional Items (1-2)</b>	2486.81	2493.31	5177.29	4525.42	9151.99
4	Other Income	42.12	63.16	63.61	102.60	373.26
5	<b>Profit before Interest &amp; Exceptional Items (3+4)</b>	2528.93	2556.47	5240.90	4628.02	9525.25
6	Interest	1198.72	693.89	2182.33	1243.81	3187.22
7	<b>Profit after Interest, but before Exceptional Items (5-6)</b>	1330.21	1862.58	3058.57	3384.21	6338.03
8	Exceptional Items	-	-	-	-	-
9	<b>Profit from Ordinary Activities before tax (7+8)</b>	1330.21	1862.58	3058.57	3384.21	6338.03
10	Tax Expenses	347.00	436.00	793.00	705.00	1393.57
11	<b>Profit from Ordinary Activities after tax (9-10)</b>	983.21	1426.58	2265.57	2679.21	4944.46
12	Extraordinary items (net of tax expense)	-	-	-	-	-
13	<b>Net Profit for the period</b>	983.21	1426.58	2265.57	2679.21	4944.46
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	1239.06	1064.06	1239.06	1064.06	1064.06
15	Reserve excluding revaluation reserves	17899.77	10902.33	17899.77	10902.33	12695.21
16	Earning per share (EPS)					
	a. Basic and diluted EPS before extraordinary items for the period	*3.85	*6.70	*9.70	*12.59	23.23
	b. Basic and diluted EPS after extraordinary items for the period.	*3.85	*6.70	*9.70	*12.59	23.23
17	Aggregate of non promoter shareholding					
	number of shares	22171810	7777036	22171810	7777036	12516051
	percentage of shareholding	89.47	36.54	89.47	36.54	58.81
18	Promoters and Promoters Group shareholding					
	a) Pledged / Encumbered					
	- Number of shares	2126606	5781588	2126606	5781588	8440541
	- Percentage of shares ( as % to the total shareholding of promoters & promoters group)	81.50	42.81	81.50	42.81	96.29
	- Percentage of shares ( as % to the total share capital of the Company)	8.58	27.17	8.58	27.17	39.66
	b) Non Encumbered					
	- Number of shares	482869	7722661	482869	7722661	324693
	- Percentage of shares ( as % to the total shareholding of promoters & promoters group)	18.50	57.19	18.50	57.19	3.71
	- Percentage of shares ( as % to the total share capital of the Company)	1.95	36.29	1.95	36.29	1.53

\* not annulised




## STATEMENT OF ASSETS AND LIABILITIES : (Rs.in Lac)

	Particulars	( Unaudited )		( Audited )
		As At		As At
		30.09.2011	30.09.2010	31.03.2011
A.	Shareholder's Funds :			
	a) Share Capital	1,239.06	1,064.06	1,064.06
	b) Share application Money ( Convertible Warrents )	-	752.50	752.50
	c) Reserve and Surplus	18,458.65	11,462.77	13,254.86
B.	Loan Funds	25,447.64	23,684.77	25,757.87
C.	Deferred Tax Liability (Net)	588.20	520.00	536.20
D.	Total [ A+B+C ]	45,733.55	37,484.10	41,365.49
E.	Fixed Assets (Net )	10,670.04	7,574.94	8,838.11
F.	Investments	1,071.84	3.79	1,071.84
G.	Current Assets :			
	a) Inventories	9,102.81	8,125.49	8,445.85
	b) Sundry Debtors	26,968.43	22,263.54	25,673.08
	c) Cash & Bank Balance	523.56	1,230.40	395.21
	d) Loans & Advances	4,447.47	5,447.81	3,406.59
	Sub-total [ G ]	41,042.27	37,067.24	37,920.73
H.	Less : Current Liabilities and Provision			
	a) Current Liabilities	4,711.61	4,216.43	4,418.30
	b) Provisions	2,338.99	2,945.44	2,046.89
	Sub-total [ H ]	7,050.60	7,161.87	6,465.19
I.	Net Current Asset [ G-H ]	33,991.67	29,905.37	31,455.54
J	Total [ E+F+I ]	45,733.55	37,484.10	41,365.49

**Notes :**

- 1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 15th November, 2011.
- 2] Provision for Tax includes Current Year Tax and Deferred Tax .
- 3] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "Segment Reporting" is considered to be the only business segment.
- 4] Between 10th June,11 to 16th June,11 the company has allotted 35,00,000 Equity Shares of Rs.5/- each at Rs. 86/- per Equity Shares as per Terms of issue of 35,00,000 Convertible Warrants, which were listed on BSE and NSE.
- 5] Briocia Pharma (India) Ltd. has become 100% subsidiary of the Company w.e.f.25th November,10. The financial results for the quarter ended 30th September,2011 of the company are prepared on standalone basis.
- 6] The above results are subject to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.
- 7] Previous year's figures have been regrouped and rearranged wherever necessary.
- 8] During the current quarter, two investor complaints were received. There was no pending investor complaint at the beginning of the quarter and at the end of the quarter.

For TWILIGHT LITAKA PHARMA LIMITED

  
 GOPAL RAMOURTI  
 Managing Director

 Place : Pune  
 Date : 15th November, 2011